The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

X.k

Sarcoid-like granulomatosis (endo-/extrathoracic)

May affect the lung, skin, heart or cause hypercalcemia exactly as does sarcoidosis

Publications

Majjad A, Bezza A, Biyi A, El Ochi MR, El Maghraoui A

Pulmonary Sarcoidosis following Etanercept Treatment for Ankylosing Spondylitis: A Case Report and Review of the Literature.

Case reports in rheumatology. 2018;2018:9867248

Watrin A, Royer M, Legrand E, Gagnadoux F

[Severe hypercalcemia revealing sarcoidosis precipitated by etanercept].

Revue des maladies respiratoires. 2014;31(3):255-8

Miyagi R, Ideguchi H, Soga T, Yamakawa Y, Otsuki H, Niino H, Shiina T, Ueda A, Ishigatsubo Y

Development of pulmonary and cardiac sarcoidosis during etanercept therapy.

International journal of rheumatic diseases. 2014;17(7):810-2

Senabre-Gallego JM, Santos-Ramírez C, Santos-Soler G, Salas-Heredia E, Sánchez-Barrioluengo M, Barber X, Rosas J, AIRE-MB group

Long-term safety and efficacy of etanercept in the treatment of ankylosing spondylitis.

Patient preference and adherence. 2013;7:961-72

Bhamra K, Stevens R

Pulmonary Sarcoidosis following Etanercept Treatment.

Case reports in rheumatology. 2012;2012:724013

Hashkes PJ, Shajrawi I

Sarcoid-related uveitis occurring during etanercept therapy.

Clinical and experimental rheumatology. 2003;21(5):645-6